0
July 1991, Vol 145, No. 7 >
Article | July 1991

Dose-Related Immunogenicity of Haemophilus influenzae Type b Capsular Polysaccharide—Neisseria meningitidis Outer Membrane Protein Conjugate Vaccine FREE

Victor K. Wong, MD; Rory Quagliata, MPH, RN; Robert Adler, MD; Kwang Sik Kim, MD
[+] Author Affiliations

Accepted for publication January 10, 1991.

Presented in part at the 29th International Conference of Antimicrobial Agents and Chemotherapy, Houston, Tex, September 18, 1989.

Reprint requests to the Division of Infectious Diseases, Childrens Hospital of Los Angeles, 4650 Sunset Blvd, Box 51, Los Angeles, CA 90027 (Dr Kim).


Am J Dis Child. 1991;145(7):734-741. doi:10.1001/archpedi.1991.02160070038018.
Text Size: A A A
Published online
Article
References
Comments

• We studied the immunologic responsiveness to Haemophilus influenzae type b capsular polysaccharide—Neisseria meningitidis group b outer membrane protein conjugate vaccine (PRP-NOMP) in children 2 to 42 months of age with vaccine dosages containing 7.5, 15, or 30 μg of PRP. Overall, PRP-NOMP was highly immunogenic. Geometric mean titers of anti-PRP antibody increased from 0.09 to 3.3 mg/L and 6.6 mg/L following each dose of vaccine, respectively, in the 2- to 18-month age group. Similarly, anti-PRP antibody geometric mean titers increased from 0.12 to 5.9 mg/L in the older than 18-month age group. However, we noted an apparent inverse relationship between vaccine dosages and immune responses following two doses of PRP-NOMP in 2- to 18-month-old children. Anti-PRP antibody geometric mean titers were 12.0,6.9, and 3.5 mg/L, respectively, after the second dose of vaccine containing 7.5,15, or 30 μg of PRP. Additional studies are needed to understand the mechanisms responsible for this inverse relationship and also to determine the optimal dosage of PRP-NOMP for young children.

(AJDC. 1991;145:742-745)

REFERENCES

1 +
Ward JI, Broome CV, Harrison LH, Shinefield H, Black S.  Haemophilus influenzae type b vaccines: lessons for the future . Pediatrics . 1988;;81:886-893.
2 +
Smith DH, Peter G, Ingram DL, Harding AL, Anderson P.  Responses of children immunized with the capsular polysaccharide of Haemophilus influenzae type b . Pediatrics . 1973;;52:637-644.
3 +
Harrison LH, Broome CV, Hightower AW, et al.  A day care-based study of the efficacy of Haemophilus b polysaccharide vaccine . JAMA . 1988;;260:1413-1418.
4 +
Osterholm MT, Rambeck JH, White KE, et al.  Lack of efficacy of Haemophilus b polysaccharide vaccine in Minnesota . JAMA . 1988;;260:1423-1428.
5 +
Black SB, Shinefeld HR, Hiatt RA, Fireman BH.  Efficacy of Haemophilus influenzae type b capsular polysaccharide vascine . Pediatr Infect Dis J . 1988;;7:149-156.
6 +
Shapiro ED, Murphy TV, Wald ER, Brady CA.  The protective efficacy of Haemophilus b polysaccharide vaccine . JAMA . 1988;;260:1419-1422.
7 +
Einhorn MS, Weinberg GA, Anderson EL, Granoff PD, Granoff DM.  Immunogenicity in infants of Haemophilus influenzae type b polysaccharide in a conjugate vaccine with Neisseria meningitides outer-membrane protein . Lancet . 1986;;2:299-302.
8 +
Lenoir AA, Granoff PD, Granoff DM.  Immunogenicity of Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in 2- to 6-month-old infants . Pediatrics . 1987;;80:283-287.
9 +
Weinberg GA, Einhorn MS, Lenoir AA, Granoff PD, Granoff DM.  Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide—Neisseria meningitides outer membrane protein conjugate vaccine . J Pediatr . 1987;;111:22-27.
10 +
Shapiro ED, Capobianco LA, Berg AT, Zitt MQ.  The immunogenicity of Hemophilus influenzae type b polysaccharide—Neisseria meningitides group B outer membrane protein complex vaccine in infants and young children . J Infect Dis . 1889;;160:1064-1067.
11 +
Kim KS, Wong VK, Adler R, Steinberg EA.  Comparative immune responses to Haemophilus influenzae type b polysaccharide and a polysaccharide-protein conjugate vaccines . Pediatrics . 1990;;85( (suppl) ):648-650.
12 +
Vella PP, Staub JM, Armstrong J, et al.  Immunogenicity of a new Haemophilus influenzae type B conjugate vaccine . Pediatrics . 1990;;85( (suppl) ):668-675.
13 +
Snedecor GW, Cochran WG, eds. Statistical Methods . 6th ed. Ames, la: Iowa State University Press; 1967;.
14 +
Kayhty H, Peltola H, Karanko V, Makela PH.  The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b . J Infect Dis . 1983;;147:1100.
15 +
Tudor-Williams G, Frankland J, Isaacs D, et al.  Haemophilus influenzae type b conjugate vaccine trial in Oxford: implications for the United Kingdom . Arch Dis Child . 1989;;64:520-524.
16 +
Taylor CE, Baker PJ.  Production of soluble suppressor factor by spleen cells from mice immunized with type III penumococcal polysaccharide . J Immunol . 1985;;135:2551-2556.
17 +
Di John D, Torres JR, Murillo, J, et al.  Effect of priming with carrier on response to conjugate vaccine . Lancet . 1989;;2:1415-1418.
18 +
MannhalterJW, Neychev HO, Zlabinger GJ,AhmadR,Eibl MM.  Modulation of the human immune response by the nontoxic and non-pyogenic adjuvant aluminum hydroxide:effect on antigen uptake and antigen presentation . Clin Exp Immunol . 1985;;61:143-151.
19 +
Stewart-Tull DES.  The immunological activities of bacterial peptidoglycans . Ann Rev Microbiol . 1980;;34:311-340.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

1 +
Ward JI, Broome CV, Harrison LH, Shinefield H, Black S.  Haemophilus influenzae type b vaccines: lessons for the future . Pediatrics . 1988;;81:886-893.
2 +
Smith DH, Peter G, Ingram DL, Harding AL, Anderson P.  Responses of children immunized with the capsular polysaccharide of Haemophilus influenzae type b . Pediatrics . 1973;;52:637-644.
3 +
Harrison LH, Broome CV, Hightower AW, et al.  A day care-based study of the efficacy of Haemophilus b polysaccharide vaccine . JAMA . 1988;;260:1413-1418.
4 +
Osterholm MT, Rambeck JH, White KE, et al.  Lack of efficacy of Haemophilus b polysaccharide vaccine in Minnesota . JAMA . 1988;;260:1423-1428.
5 +
Black SB, Shinefeld HR, Hiatt RA, Fireman BH.  Efficacy of Haemophilus influenzae type b capsular polysaccharide vascine . Pediatr Infect Dis J . 1988;;7:149-156.
6 +
Shapiro ED, Murphy TV, Wald ER, Brady CA.  The protective efficacy of Haemophilus b polysaccharide vaccine . JAMA . 1988;;260:1419-1422.
7 +
Einhorn MS, Weinberg GA, Anderson EL, Granoff PD, Granoff DM.  Immunogenicity in infants of Haemophilus influenzae type b polysaccharide in a conjugate vaccine with Neisseria meningitides outer-membrane protein . Lancet . 1986;;2:299-302.
8 +
Lenoir AA, Granoff PD, Granoff DM.  Immunogenicity of Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in 2- to 6-month-old infants . Pediatrics . 1987;;80:283-287.
9 +
Weinberg GA, Einhorn MS, Lenoir AA, Granoff PD, Granoff DM.  Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide—Neisseria meningitides outer membrane protein conjugate vaccine . J Pediatr . 1987;;111:22-27.
10 +
Shapiro ED, Capobianco LA, Berg AT, Zitt MQ.  The immunogenicity of Hemophilus influenzae type b polysaccharide—Neisseria meningitides group B outer membrane protein complex vaccine in infants and young children . J Infect Dis . 1889;;160:1064-1067.
11 +
Kim KS, Wong VK, Adler R, Steinberg EA.  Comparative immune responses to Haemophilus influenzae type b polysaccharide and a polysaccharide-protein conjugate vaccines . Pediatrics . 1990;;85( (suppl) ):648-650.
12 +
Vella PP, Staub JM, Armstrong J, et al.  Immunogenicity of a new Haemophilus influenzae type B conjugate vaccine . Pediatrics . 1990;;85( (suppl) ):668-675.
13 +
Snedecor GW, Cochran WG, eds. Statistical Methods . 6th ed. Ames, la: Iowa State University Press; 1967;.
14 +
Kayhty H, Peltola H, Karanko V, Makela PH.  The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b . J Infect Dis . 1983;;147:1100.
15 +
Tudor-Williams G, Frankland J, Isaacs D, et al.  Haemophilus influenzae type b conjugate vaccine trial in Oxford: implications for the United Kingdom . Arch Dis Child . 1989;;64:520-524.
16 +
Taylor CE, Baker PJ.  Production of soluble suppressor factor by spleen cells from mice immunized with type III penumococcal polysaccharide . J Immunol . 1985;;135:2551-2556.
17 +
Di John D, Torres JR, Murillo, J, et al.  Effect of priming with carrier on response to conjugate vaccine . Lancet . 1989;;2:1415-1418.
18 +
MannhalterJW, Neychev HO, Zlabinger GJ,AhmadR,Eibl MM.  Modulation of the human immune response by the nontoxic and non-pyogenic adjuvant aluminum hydroxide:effect on antigen uptake and antigen presentation . Clin Exp Immunol . 1985;;61:143-151.
19 +
Stewart-Tull DES.  The immunological activities of bacterial peptidoglycans . Ann Rev Microbiol . 1980;;34:311-340.

Correspondence

Submit a Letter
CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Clear Answers | Save For Later
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

© 2013 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems